NCT00904176View on ClinicalTrials.gov

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin

Tablets, Oral, 20 mg, followed by 10 mg, Single Dose

DRUG

Warfarin

Tablets, Oral, 25 mg, Single Dose

DRUG

Digoxin

Tablets, Oral, 0.25, Single Dose

Trial Locations (1)

66219

Pra International, Lenexa

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY